Future Perspectives for Antiangiogenic Therapy in Retinal Diseases

The World Health Organization considers eye disorders as the serious problem of our time [1]. According to world statistics, the number of people with visual impairment is 1.3 billion, most of this number are people over 50 years old [2]. Over the past 20 years, developments in the treatment of AMD and fundus diseases have advanced and include drugs such as vascular endothelial growth factor inhibitors. The molecular structures of drugs intended for intravitreal use range from RNA aptamers (pegaptanib) to full-length monoclonal antibodies (mAb: bevacizumab) to Fab fragments (ranibizumab) and an antibody conjugate (aflibercept). In addition, single-chain variable fragment (scFv: brolucizumab), bispecific monoclonal antibody (faricimab) and DARPin (abigar pegol) show promising results in clinical trials.[6],[7] Brolucizumab (RTH258) was developed by ESBATech (ES-BATech AG — Schlieren ZH, Switzerland) originally under the name ESBA1008, an inhibitor of the humanized single chain antibody fragment (scFv) of all isoforms of vascular endothelial growth factor-A (VEGF-A). [6],[7],[11]. The Faricimab (ROCHE, Switzerland) molecule is characterized by the presence of a bispecific antibody that simultaneously binds to both VEGF-A and Ang-2; the drug consists of an anti-Ang-2 antigen-binding fragment (Fab), an anti-VEGF-A Fab and a crystallizing modified fragment (Fc region) with a total size of 150 kDa. This “crossover” effect provided high affinity for both targets while also maintaining a good stability profile compared to natural antibodies [8]. Abicipar Pegol (Abicipar, Allergan. Dublin, Ireland) is a DARPin aimed at binding all VEGF-A isoforms, like ranibizumab. It has a higher affinity and a longer half-life from the eye than ranibizumab (>13 days versus 7.2 days), making it a potential drug with a longer duration of action and the need for less frequent injections [15]. In this article, we tried to summarize the literature data on new anti-VEGF drugs being developed and ready for release. We hope that the appearance of these drugs on the market will make it possible to reduce the injection load on the patient and optimize their material costs.

1. Petrachkova M.S., Saidasheva E.I., Petrachkov D.V., Buyanovskaya S.V. Modern approaches to predicting the development of active type 1 retinopathy of prematurity. Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(4):50–59 (In Russ.). DOI: 10.17116/oftalma201913504150

2. Gamidov AA, Durzhinskaya MH, Makashova NV, Sakalova ED, Velieva IA. Persistent vitreous artery in an adult (clinical observation). Annals of Ophthalmology = Vestnik oftal’mologii. 2020;4(2):214–218 (In Russ.). DOI: 10.17116/oftalma2020136042214

3. Sheremet N.L., Mikaelyan A.A., Andreev A.Yu., Kiselev S.L. Possibilities of treating retinal diseases in patients with damaged retinal pigment epithelium. Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5-2):226–234 (In Russ.). DOI: 10.17116/oftalma2019135052226

4. Samanta A., Aziz A.A., Jhingan M., Singh S.R., Khanani A.M., Chhablani J. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):250–259. DOI: 10.1097/APO.0000000000000291

5. Bubnova I.A., Kurguzova A.G. Сhanges in intraocular pressure after intravitreal injections. Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(4):47–51 (In Russ.). DOI: 10.17116/oftalma201813404147

6. Kim H.M., Woo S.J. Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics. 2021 Jan 15;13(1):108. DOI: 10.3390/pharmaceutics13010108

7. Khan M., Aziz A.A., Shafi N.A., Abbas T., Khanani A.M. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020 Aug 10;9(8):1869. DOI: 10.3390/cells9081869

8. Al-Khersan H., Hussain R.M., Ciulla T.A., Dugel P.U. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019 Oct;20(15):1879–1891. DOI: 10.1080/14656566.2019.1636031

9. Campa C. New Anti-VEGF Drugs in Ophthalmology. Curr Drug Targets. 2020;21(12):1194–1200. DOI: 10.2174/1389450121666200428101738

10. Bulirsch L.M., Saßmannshausen M., Nadal J. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. British Journal of Ophthalmology Published Online First: 12 April 2021. DOI: 10.1136/bjophthalmol-2020-318672

11. Garweg J.G. A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE). Klin Monbl Augenheilkd. 2020 Apr;237(4):450–453. DOI: 10.1055/a-1101-9126

12. Holz F.G., Dugel P.U., Weissgerber G., Hamilton R., Silva R., Bandello F., Larsen M., Weichselberger A., Wenzel A., Schmidt A. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology. 2016;123:1080–1089. DOI: 10.1016/j.ophtha.2015.12.030

13. Nicolò M., Ferro Desideri L., Vagge A., Traverso C.E. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193–200. DOI: 10.1080/13543784.2021.1879791

14. Sharma A., Kumar N., Kuppermann B.D., Bandello F., Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020 May;34(5):802–804. DOI: 10.1038/s41433-019-0670-1

15. Khanani A.M., Patel S.S., Ferrone P.J., Osborne A., Sahni J., Grzeschik S., Basu K., Ehrlich J.S., Haskova Z., Dugel P.U. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2020 Sep 1;138(9):964–972. DOI: 10.1001/jamaophthalmol.2020.2699

16. Ferro Desideri L., Traverso C.E., Nicolò M. Abicipar pegol: an investigational antiVEGF agent for the treatment of wet age-related macular degeneration. Expert Opin Investig Drugs. 2020 Jul;29(7):651–658. DOI: 10.1080/13543784.2020.1772754

17. Hussain R.M., Weng C.Y., Wykoff C.C., Gandhi R.A., Hariprasad S.M. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 Sep;20(9):999–1008. DOI: 10.1080/14712598.2020.1782379